Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   42312   clinical trials with a EudraCT protocol, of which   6968   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2014-000255-85
    Sponsor's Protocol Code Number:54767414MMY3004
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2014-06-13
    Trial results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2014-000255-85
    A.3Full title of the trial
    Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma
    Ensayo fase 3 para comparar Daratumumab, Bortezomib y dexametasona (DVd) frente a Bortezomib y dexametasona (Vd) en sujetos con mieloma múltiple en recaída o refractario
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) with Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma
    Ensayo para comparar Daratumumab, Bortezomib y dexametasona (DVd) frente a Bortezomib y dexametasona (Vd) en sujetos con mieloma múltiple en recaída o refractario
    A.3.2Name or abbreviated title of the trial where available
    CASTOR Trial
    Ensayo CASTOR
    A.4.1Sponsor's protocol code number54767414MMY3004
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJanssen-Cilag International N.V.
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJanssen Research & Development, LLC
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationJanssen-Cilag International N.V.
    B.5.2Functional name of contact pointClinical Registry group
    B.5.3 Address:
    B.5.3.1Street AddressArchimedesweg 29
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2333
    B.5.4Telephone number+34917228100
    B.5.5Fax number+34917228628
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/13/1153
    D.3 Description of the IMP
    D.3.1Product nameDaratumumab
    D.3.2Product code HuMax-CD38
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDaratumumab
    D.3.9.1CAS number 945721-28-8
    D.3.9.2Current sponsor codeJNJ-54767414 (Daratumumab)
    D.3.9.3Other descriptive nameHUMAX-CD38
    D.3.9.4EV Substance CodeSUB29447
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D. medicinal product typehuman monoclonal antibody
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Multiple myeloma
    Mieloma Múltiple
    E.1.1.1Medical condition in easily understood language
    Multiple myeloma
    Mieloma Múltiple
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 17.0
    E.1.2Level LLT
    E.1.2Classification code 10028228
    E.1.2Term Multiple myeloma
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the efficacy of daratumumab when combined with VELCADE and dexamethasone (DVd) to that of VELCADE and dexamethasone (Vd), in terms of progression-free survival (PFS) in subjects with relapsed or refractory multiple myeloma.
    El objetivo principal es comparar la eficacia de daratumumab combinado con VELCADE (bortezomib) y dexametasona (DVd) con la de VELCADE y dexametasona (Vd) en la supervivencia libre de progresión (SSP) en sujetos con mieloma múltiple en recaída o refractario al tratamiento.
    E.2.2Secondary objectives of the trial
    The major secondary objectives are as follows:
    - To evaluate clinical outcomes including time to disease progression (TTP), overall response rate (ORR), and overall survival (OS).
    - To evaluate the proportion of subjects with a response of very good partial response (VGPR) or better.
    - To evaluate duration of and time to response.
    - To assess the safety and tolerability of daratumumab when administered in combination with Vd.
    - To assess Minimal Residual Disease (MRD) in subjects who achieve ?VGPR.
    - To assess the pharmacokinetics of daratumumab in combination with Vd.
    - To assess the immunogenicity of daratumumab.
    - To evaluate treatment effects on patient reported outcomes (PROs) including the EuroQol-5 Dimensions (EQ-5D-5L) and EORTC QLQ-C30.
    - To evaluate clinical efficacy of DVd in high risk molecular subgroups (del17p, t(4;14), t(14;20), UAMS-70).
    ? Evaluar los criterios de valoración clínicos, incluidos el tiempo hasta la progresión de la enfermedad (TPE), la tasa de respuesta global (TRG) y la supervivencia global (SG).
    ? Evaluar la proporción de sujetos con una respuesta parcial muy buena (RPMB) o mejor.
    ? Evaluar la duración de la respuesta y el tiempo hasta la respuesta.
    ? Evaluar la seguridad y la tolerabilidad de daratumumab cuando se administra combinado con Vd.
    ? Evaluar la enfermedad residual mínima (ERM) en sujetos que logren una respuesta ? RPMB.
    ? Evaluar la farmacocinética de daratumumab en combinación con Vd.
    ? Evaluar la inmunogenicidad de daratumumab.
    ? Evaluar los efectos del tratamiento en los resultados comunicados por el paciente (RCP), incluidas las puntuaciones obtenidas en los cuestionarios EuroQol-5 Dimensiones (EQ-5D-5L) y EORTC QLQ-C30.
    ? Evaluar la eficacia clínica de DVd en subgrupos moleculares de alto riesgo (del17p, t(4;14), t(14;20), UAMS-70).
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Must have documented multiple myeloma
    - Must have received at least 1 prior line of therapy for multiple myeloma
    - Must have documented evidence of progressive disease as defined by the
    International Myeloma Working Group criteria on or after their last regimen - Must have an Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2
    - Must have achieved a response (partial response or better) to at least 1 prior regimen
    - El sujeto deberá tener mieloma múltiple comprobado,
    - El sujeto deberá haber recibido al menos una línea previa de tratamiento para el mieloma múltiple
    - El sujeto deberá tener pruebas documentadas de progresión de la enfermedad (PE), definida por los criterios del IMWG, en o después del último régimen.
    - El sujeto deberá tener una puntuación del estado funcional del ECOG de 0, 1 ó 2.
    - El sujeto deberá haber conseguido una respuesta (respuesta parcial [RP] o mejor) al menos a un régimen previo
    E.4Principal exclusion criteria
    - Has received daratumumab or other anti-CD38 therapies previously
    - Is refractory to VELCADE (had progression of disease while receiving VELCADE therapy or within 60 days of ending VELCADE therapy
    - Is intolerant to VELCADE (ie, discontinued due to any adverse event while on VELCADE treatment)
    - Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the date of randomization
    - Has a history of malignancy (other than multiple myeloma) within 3 years before the date of randomization
    - Has any concurrent medical condition or disease (eg, active systemic infection) that is likely to interfere with study procedures
    - El sujeto ha recibido previamente daratumumab u otros tratamientos anti-CD38.
    - El sujeto no responde a VELCADE (es decir, el sujeto presenta progresión de la enfermedad durante el tratamiento con VELCADE o en los 60 días siguientes a la finalización del tratamiento con VELCADE).
    - El sujeto es intolerante a VELCADE (es decir, ha tenido que suspender la medicación por algún acontecimiento adverso aparecido durante el tratamiento con VELCADE).
    - El sujeto ha recibido tratamiento contra el mieloma en las dos semanas o cinco semividas farmacocinéticas del tratamiento previas a la fecha de aleatorización, lo que sea más largo.
    - El sujeto tiene antecedentes de neoplasia maligna (distinta del mieloma múltiple) en los tres años previos a la fecha de aleatorización.
    - El sujeto sufre cualquier proceso médico o enfermedad concurrente (p. ej., infección sistémica activa) que es probable que interfiera en los procedimientos del estudio.
    E.5 End points
    E.5.1Primary end point(s)
    Percentage of participants with progression-free survival (PFS)
    Porcentaje de participantes con supervivencia libre de progresión (SLP)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Baseline, up to the end of the study
    Visita basal, hasta el final del estudio
    E.5.2Secondary end point(s)
    1. Time to disease progression (TTP)
    2. Percentage of Participants With Overall Response
    3. Duration of response
    4. Time to Response
    5. Percentage of participants with a very good partial response (VGPR) or better
    6. Percentage of participants with Minimal Residual Disease (MRD)
    7. Percentage of participants with overall survival (OS)
    1. Tiempo hasta la progresión de la enfermedad
    2. Tasa de respuesta global.
    3. Duración de la respuesta.
    4. Tiempo hasta la respuesta.
    5. Proporción de participantes con respuesta parcial muy buena (RPMB) o mejor.
    6. Proporción de participantes con enfermedad mínima residual (EMR).
    7. Proporción de sujetos con supervivencia global (SG)
    E.5.2.1Timepoint(s) of evaluation of this end point
    - For all secondary end points except 4 is Baseline, up to the end of the study
    - for secondary end point 4 is Baseline until first documented response
    - Para todos los objetivos secundarios excepto el 4, desde la visita basal hasta el fin del estudio.
    - Para el objetivo secundario 4 desde la visita basal hasta la primera respuesta documentada
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA78
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Czech Republic
    Korea, Republic of
    Russian Federation
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    the following is included in the protocol : The study is considered completed after 320 deaths have occurred.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days27
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days27
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 192
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 288
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 300
    F.4.2.2In the whole clinical trial 480
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Daratumumab will be provided to patients who are benefiting from the drug at the end of study .
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-08-26
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-08-06
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice